Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

By Ward Alexandra   O’Brien Judith A   Salas Maribel  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3705-3715

Bentham Science Publishers

Access to resources Recommend Favorite

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

By Tanizawa Yukio   Kaku Kohei   Araki Eiichi   Tobe Kazuyuki   Terauchi Yasuo   Utsunomiya Kazunori   Iwamoto Yasuhiko   Watada Hirotaka   Ohtsuka Wataru   Watanabe Daisuke   Suganami Hideki  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 749-766

Informa Healthcare

Access to resources Recommend Favorite

Benefits and Risks of Transfer from Oral Agents to Insulin in Type 2 Diabetes Mellitus

By Evans A.   Krentz A.J.  

Drug Safety, Vol. 21, Iss. 1, 1999-07 ,pp. : 7-22

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite